Free Trial

Vir Biotechnology (VIR) News Today

Vir Biotechnology logo
$4.62 +0.13 (+2.78%)
As of 03:47 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

VIR Latest News

Vir Biotechnology, Inc. stock logo
Millennium Management LLC Has $12.59 Million Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)
Millennium Management LLC increased its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 55.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,715,083 shares of the company's stock after purchasing an addi
Vir Biotechnology, Inc. stock logo
Vir Biotechnology's (VIR) Buy Rating Reaffirmed at Needham & Company LLC
Needham & Company LLC reiterated a "buy" rating and set a $14.00 target price on shares of Vir Biotechnology in a research report on Thursday.
Vir Biotechnology, Inc. stock logo
HC Wainwright Has Optimistic Outlook of VIR Q2 Earnings
Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - Investment analysts at HC Wainwright increased their Q2 2025 EPS estimates for shares of Vir Biotechnology in a research report issued to clients and investors on Tuesday, May 20th. HC Wainwright analyst P. Trucchio now anticipates that the com
Vir Biotechnology, Inc. stock logo
Point72 Asset Management L.P. Raises Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)
Point72 Asset Management L.P. lifted its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 16,169.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 848,454 shares of the company's stock after buying an additional 843,
Vir Biotechnology, Inc. stock logo
Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by D. E. Shaw & Co. Inc.
D. E. Shaw & Co. Inc. lowered its position in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 46.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 502,000 shares of the company's stock after selling 428,655 shares du
Vir Biotechnology, Inc. stock logo
Stonepine Capital Management LLC Takes Position in Vir Biotechnology, Inc. (NASDAQ:VIR)
Stonepine Capital Management LLC acquired a new stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 164,106 shares of the company's stock
Vir Biotechnology, Inc. stock logo
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Recommendation of "Moderate Buy" from Brokerages
Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and six have issued a
Vir Biotechnology, Inc. stock logo
Sphera Funds Management LTD. Boosts Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)
Sphera Funds Management LTD. boosted its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 523.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 581,829 shares of the company's sto
Vir Biotechnology, Inc. stock logo
Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by Algert Global LLC
Algert Global LLC lessened its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 90.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 19,802 shares of the company's stock after selling 193,663 shares during the q
Vir Biotechnology, Inc. stock logo
Orbimed Advisors LLC Reduces Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)
Orbimed Advisors LLC reduced its position in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 9.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,218,617 shares of the company's stock after selling 354,383 shar
Vir Biotechnology, Inc. stock logo
Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Acquired by Hudson Bay Capital Management LP
Hudson Bay Capital Management LP increased its stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 60.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 849,873 shares of the compa
Vir Biotechnology, Inc. stock logo
Vir Biotechnology (NASDAQ:VIR) Given New $14.00 Price Target at Needham & Company LLC
Needham & Company LLC lowered their price objective on shares of Vir Biotechnology from $19.00 to $14.00 and set a "buy" rating for the company in a research report on Monday.
Vir Biotechnology, Inc. stock logo
Bridgeway Capital Management LLC Sells 66,538 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)
Bridgeway Capital Management LLC lessened its stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 20.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 263,243 shares of the company's stock after selling 66,538
Vir Biotechnology, Inc. stock logo
Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP grew its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 58.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,915,465 shares of the company's stock after purchasing an additional 703,360
Vir Biotechnology, Inc. stock logo
DAFNA Capital Management LLC Invests $734,000 in Vir Biotechnology, Inc. (NASDAQ:VIR)
DAFNA Capital Management LLC purchased a new position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 100,000 shares of the company's stock, val
Q1 2025 Vir Biotechnology Inc Earnings Call
Vir Biotechnology, Inc. stock logo
1,084,539 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Bought by Baker BROS. Advisors LP
Baker BROS. Advisors LP bought a new stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 1,084,539 shares of the company's stock, valued at approximately $7,961,000. Baker BROS.
Vir Biotechnology, Inc. stock logo
Wells Fargo & Company MN Has $387,000 Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)
Wells Fargo & Company MN trimmed its stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 79.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 52,661 shares of the company's stock after selling 199,096 shares
Vir Biotechnology, Inc. stock logo
Barclays PLC Has $1.62 Million Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)
Barclays PLC reduced its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 59.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 221,178 shares of the company's stock after selling 329,008 shares during the quarter. Barclays PLC ow
Vir Biotechnology, Inc. stock logo
Susquehanna Fundamental Investments LLC Invests $1.48 Million in Vir Biotechnology, Inc. (NASDAQ:VIR)
Susquehanna Fundamental Investments LLC purchased a new position in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 201,185 shares
Vir Biotechnology, Inc. stock logo
Tower Research Capital LLC TRC Has $451,000 Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)
Tower Research Capital LLC TRC increased its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 308.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 61,391 shares of the company's stock after pu
Vir Biotechnology, Inc. stock logo
Vir Biotechnology (VIR) to Release Earnings on Thursday
Vir Biotechnology (NASDAQ:VIR) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-vir-biotechnology-inc-stock/)
Vir Biotechnology, Inc. stock logo
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Analysts
Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company
Vir Biotechnology, Inc. stock logo
Vir Biotechnology (NASDAQ:VIR) Shares Up 5.5% - Here's What Happened
Vir Biotechnology (NASDAQ:VIR) Stock Price Up 5.5% - Should You Buy?
Vir Biotechnology, Inc. stock logo
Vir Biotechnology, Inc. (NASDAQ:VIR) Short Interest Up 28.3% in March
Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) saw a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 10,110,000 shares, an increase of 28.3% from the March 15th total of 7,880,000 shares. Currently, 11.6% of the company's shares are sold short. Based on an average trading volume of 2,080,000 shares, the days-to-cover ratio is presently 4.9 days.
Vir Biotechnology, Inc. stock logo
Walleye Capital LLC Increases Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)
Walleye Capital LLC increased its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 2,119.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 434,460 shares of the company's stock after buying an
Vir Biotechnology, Inc. stock logo
Renaissance Technologies LLC Buys 55,300 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)
Renaissance Technologies LLC raised its stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 4.7% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 1,237,600 shares of the company's stock after purchasing an additional 55,300 shares during
Vir Biotechnology, Inc. stock logo
Quinn Opportunity Partners LLC Purchases Shares of 65,976 Vir Biotechnology, Inc. (NASDAQ:VIR)
Quinn Opportunity Partners LLC acquired a new position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 65,976 shares of the company's stock, valued at approximate
Vir Biotechnology, Inc. stock logo
ExodusPoint Capital Management LP Makes New Investment in Vir Biotechnology, Inc. (NASDAQ:VIR)
ExodusPoint Capital Management LP bought a new stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 246,833 shares of the company's stock, valued at approximately
Vir Biotechnology, Inc. stock logo
Vir Biotechnology (NASDAQ:VIR) Sets New 1-Year Low - Here's Why
Vir Biotechnology (NASDAQ:VIR) Reaches New 1-Year Low - Time to Sell?
Vir Biotechnology, Inc. stock logo
ADAR1 Capital Management LLC Sells 255,118 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)
ADAR1 Capital Management LLC reduced its stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 79.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 64,067 shares of the company's stock afte
Vir Biotechnology, Inc. stock logo
Vir Biotechnology, Inc. (NASDAQ:VIR) CEO Sells $474,286.40 in Stock
Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) CEO Backer Marianne De sold 79,712 shares of the business's stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $5.95, for a total transaction of $474,286.40. Following the completion of the sale, the chief executive officer now owns 769,505 shares in the company, valued at approximately $4,578,554.75. This trade represents a 9.39 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Vir Biotechnology, Inc. stock logo
Prudential Financial Inc. Sells 180,800 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)
Prudential Financial Inc. lowered its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 42.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 244,569 shares of the company's stock after selling
Vir Biotechnology, Inc. stock logo
Vir Biotechnology (NASDAQ:VIR) Reaches New 1-Year Low - Here's What Happened
Vir Biotechnology (NASDAQ:VIR) Hits New 1-Year Low - Time to Sell?
Stock Movers: Moderna, Tesla, Canada Goose
Get Vir Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter.

VIR Media Mentions By Week

VIR Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

VIR
News Sentiment

0.96

0.78

Average
Medical
News Sentiment

VIR News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

VIR Articles
This Week

11

5

VIR Articles
Average Week

Get Vir Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:VIR) was last updated on 5/27/2025 by MarketBeat.com Staff
From Our Partners